InflaRx Highlights Data From Phase 3 Study Of Vilobelimab In Pyoderma Gangrenosum At 2026 AAD Annual Meeting

InflaRx N.V. (NASDAQ: IFRX) presented data from its Phase 3 study of vilobelimab for pyoderma gangrenosum at the 2026 AAD Annual Meeting. The findings indicated promising clinical activity, showing higher rates of complete remission, target ulcer closure, and reductions in ulcer volume, alongside a positive safety profile.